COMMUNIQUÉS West-GlobeNewswire

Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
03/06/2024
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) [...]
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
03/06/2024
PRESS RELEASE BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage The seed round was co-led by UI Investissement (via the Pertinence Invest 2 Fund [...]
BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique
03/06/2024
COMMUNIQUÉ DE PRESSE BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique Ce tour de table a été réalisé par UI Investissement ( via le fonds Pertinence [...]
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
03/06/2024
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) TACTI-004 Phase III trial will enrol [...]
Mesoblast Corporate Presentation at Investor Conference
03/06/2024
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that [...]
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
03/06/2024
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) ( [...]
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
03/06/2024
MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the [...]
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
02/06/2024
Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates p atients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination [...]
Le congrès de l’EAACI débute à Valence, en Espagne
02/06/2024
La médecine personnalisée, l’immunothérapie et l’intelligence artificielle (IA) : des thèmes clés VALENCE, Espagne, 02 juin 2024 (GLOBE NEWSWIRE) -- Le congrès international de l’EAACI a débuté sous le slogan « [...]
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
02/06/2024
The HEAD registry, with nearly 800 patients, serves to evaluate the economic and social impact of allergies at a European level VALENCIA, Spain, June 02, 2024 (GLOBE NEWSWIRE) -- Allergic diseases cost between 1,823€ [...]
Merus : présentation des données provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab lors du congrès annuel 2024 de l’ASCO®
02/06/2024
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 02 juin 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus, la Société, nous, ou notre », une société spécialisée dans l’oncologie au stade [...]
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
02/06/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length [...]
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
02/06/2024
JEDDAH, Saudi Arabia, June 02, 2024 (GLOBE NEWSWIRE) -- In an era where healthcare innovation is paramount, KFSHRC Jeddah has made headway in the treatment of severe Xanthoma through the deployment of a modified plasma [...]
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
02/06/2024
Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects REDWOOD CITY, Calif., June 02, 2024 ( [...]
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
02/06/2024
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M. [...]
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
02/06/2024
HER2 status was accurately assessed in 172 patients with advanced breast, gastroesophageal, and ovarian cancers ER status was accurately assessed and the level of ER pathway activation quantified in 87 patients with [...]
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
02/06/2024
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line [...]
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
02/06/2024
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data further support [...]
ImPact Biotech Presents Additional Interim Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
02/06/2024
Promising response rate in patients with low-grade upper tract urothelial cancer (UTUC); complete response (CR) observed in 77% (10/13) of patients who completed the Induction Treatment Phase Padeliporfin VTP safe and [...]

Pages